Skip to main content

Table 1 Patient followed up/follow-up information

From: Persistency, medication prescribing patterns, and medical resource use associated with multiple sclerosis patients receiving oral disease-modifying therapies: a retrospective medical record review

 

Total

FTY

DMF

TFN

P-value (3 groups)

(N = 293)

(N = 101)

(N = 133)

(N = 59)

Index date, (SD)

7/11/2013 (180 days)

6/6/2013 (235 days)

8/15/2013a (128 days)

6/29/2013 (159 days)

0.0370

Enrollment end date, (SD)

7/4/2014 (17 days)

7/5/2014 (17 days)

7/3/2014 (16 days)

7/5/2014 (20 days)

0.1326

Mean follow-up duration, days (SD)

357.6 (176.5)

393.5 (229.8)

323.0 (123.6)

371.3 (156.9)

0.0300

Patients enrolled at least X months, n (%)

     

 3 months

281 (95.9)

98 (97.0)

124 (93.2)

59 (100)

0.0720

 6 months

236 (80.5)

79 (78.2)

106 (79.7)

51 (86.4)

0.4235

 9 months

188 (64.2)

63 (62.3)

85 (63.9)

40 (67.8)

0.7856

 12 months

151 (51.5)

55 (54.5)

65 (48.9)

31 (52.5)

0.6885

  1. DMF dimethyl fumarate, FTY fingolimod, TFN teriflunomide
  2. a n = 128